J Korean Acad Rehabil Med.
2006 Oct;30(5):491-495.
The Effect of Vitamin K2 in Addition to Risedronate on the Patients with Postmenopausal Osteoporosis
- Affiliations
-
- 1Department of Physical Medicine and Rehabilitation, Dong-A University College of Medicine, Korea. ryukh74@nate.com
Abstract
OBJECTIVE
To assess the effect of vitamin K2 in addition to risedronate on postmenopausal osteoporosis METHOD: We enrolled 21 postmenopausal osteoporosis women (age: 65.2+/-7.8 years). Ten subjects received risedronate (35 mg, weekly) and vitamin K2 (45 mg, daily) and eleven subjects only received risedronate. They all received calcium citrate 2,130 mg and vitamin D 600 IU daily. The duration of treatment was 7.7+/-1.4 months. Bone mineral density (BMD) of lumbar spine and both femurs, serum osteocalcin and urine deoxypyridinoline were examined at baseline and after treatment.
RESULTS
After treatment, BMD, serum osteocalcin and urine deoxypyridinoline were improved in each group but there was no statistical difference between the groups.
CONCLUSION
There was no evidence of the benefit of vitamin K2 in addition to risedronate in bone metabolism on postmenopausal osteoporosis.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Combined Treatment with Vitamin K2 and Bisphosphonate in Postmenopausal Women with Osteoporosis
- Comparison of the Effect of Vitamin K2 and Risedronate on Trabecular Bone in Glucocorticoid-Treated Rats: A Bone Histomorphometry Study
- Effects of Vitamin K2 on the Development of Osteopenia in Rats as the Models of Osteoporosis
- The Vitamin D perception survey on Korean postmenopausal women in the treatment of osteoporosis
- The Therapeutic Effect of Menatetrenone (Vitamin K2) on Posttransplant Osteoporosis in Renal Transplant Recipient
